Safety and immunologic effects of high- vs low-dose cholecalciferol in multiple sclerosis
Citation Manager Formats
Make Comment
See Comments

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Abstract
Objective: To study the safety profile and characterize the immunologic effects of high- vs low-dose cholecalciferol supplementation in patients with multiple sclerosis (MS).
Methods: In this double-blind, single-center randomized pilot study, 40 patients with relapsing-remitting MS were randomized to receive 10,400 IU or 800 IU cholecalciferol daily for 6 months. Assessments were performed at baseline and 3 and 6 months.
Results: Mean increase of 25-hydroxyvitamin D levels from baseline to final visit was larger in the high-dose group (34.9 ng/mL; 95% confidence interval [CI] 25.0–44.7 ng/mL) than in the low-dose group (6.9 ng/mL; 95% CI 1.0–13.7 ng/mL). Adverse events were minor and did not differ between the 2 groups. Two relapses occurred, one in each treatment arm. In the high-dose group, we found a reduction in the proportion of interleukin-17+CD4+ T cells (p = 0.016), CD161+CD4+ T cells (p = 0.03), and effector memory CD4+ T cells (p = 0.021) with a concomitant increase in the proportion of central memory CD4+ T cells (p = 0.018) and naive CD4+ T cells (p = 0.04). These effects were not observed in the low-dose group.
Conclusions: Cholecalciferol supplementation with 10,400 IU daily is safe and tolerable in patients with MS and exhibits in vivo pleiotropic immunomodulatory effects in MS, which include reduction of interleukin-17 production by CD4+ T cells and decreased proportion of effector memory CD4+ T cells with concomitant increase in central memory CD4+ T cells and naive CD4+ T cells.
Classification of evidence: This study provides Class I evidence that cholecalciferol supplementation with 10,400 IU daily is safe and well-tolerated in patients with MS and exhibits in vivo pleiotropic immunomodulatory effects.
GLOSSARY
- 25(OH)D=
- 25-hydroxyvitamin D;
- CI=
- confidence interval;
- EAE=
- experimental autoimmune encephalitis;
- IFN=
- interferon;
- IL=
- interleukin;
- IND=
- investigational new drug application;
- LOWESS=
- locally weighted scatterplot smoothing;
- MHC=
- major histocompatibility complex;
- MS=
- multiple sclerosis;
- PBMC=
- peripheral blood mononuclear cells
Footnotes
↵* These authors contributed equally to this work.
Go to Neurology.org for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.
Supplemental data at Neurology.org
- Received May 25, 2015.
- Accepted in final form October 5, 2015.
- © 2015 American Academy of Neurology
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)
Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here
Purchase
Individual access to articles is available through the Add to Cart option on the article page. Access for 1 day (from the computer you are currently using) is US$ 39.00. Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means. The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use. Distributing copies (electronic or otherwise) of the article is not allowed.
Letters: Rapid online correspondence
- Author response to Drs. Golan & Miller
- Elias S. Sotirchos, Johns Hopkins University School of Medicineess@jhmi.edu
- P Bhargava, Baltimore, MD; PA Calabresi, Baltimore, MD
Submitted May 11, 2016 - Re:Vitamin-D supplementation: Is the MS community studying too high a dose?
- Elias S. Sotirchos, Johns Hopkins University School of Medicineess@jhmi.edu
- Peter A. Calabresi, Baltimore, MD
Submitted April 26, 2016 - Vitamin-D supplementation: Is the MS community studying too high a dose?
- Daniel Kantor, President, Kantor Neurologyinfo@KantorNeurology.com
Submitted April 12, 2016 - The influence of Vitamin D supplementation on Th-17 cell activity in patients with Multiple Sclerosis
- Daniel Golan, 1.Division of Neuroimmunology & Multiple Sclerosis Center, Lady Davis Carmel Medical Center, Haifa,golan.daniel@gmail.com
- Ariel Miller, Haifa, Israel
Submitted February 25, 2016 - Re: Vitamin D and MS: Not all is hunky dory
- Elias S. Sotirchos, Johns Hopkins University School of Medicine, Baltimore, MDess@jhmi.edu
- Pavan Bhargava, Baltimore, MD; Peter A. Calabresi, Baltimore, MD;
Submitted February 22, 2016 - Vitamin D and MS: Not all is hunky dory
- Jagannadha Avasarala, Associate Professor of Neurology, Greenville Health Systemjavasarala@ghs.org
Submitted February 04, 2016
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
More Online
Dr. Nicole Sur and Dr. Mausaminben Hathidara
► Watch
Topics Discussed
Alert Me
Recommended articles
-
Article
Interleukin-15 enhances proinflammatory T-cell responses in patients with MS and EAECyril Laurent, Gabrielle Deblois, Marie-Laure Clénet et al.Neurology: Neuroimmunology & Neuroinflammation, December 15, 2020 -
Article
Effect of dimethyl fumarate on lymphocytes in RRMSImplications for clinical practiceDevangi Mehta, Catherine Miller, Douglas L. Arnold et al.Neurology, March 27, 2019 -
Articles
Two randomized vitamin D trials in ambulatory patients on anticonvulsantsImpact on boneM. A. Mikati, L. Dib, B. Yamout et al.Neurology, December 11, 2006 -
Articles
A randomized trial of high-dose vitamin D2 in relapsing-remitting multiple sclerosisM.S. Stein, Y. Liu, O.M. Gray et al.Neurology, October 24, 2011